Compare First Solar, Inc. (FSLR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
First Solar, Inc. vs BIO-TECHNE Corp — how do they compare? First Solar, Inc. trades at $180.12 (market cap $19.36B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: First Solar, Inc. is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while First Solar, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Solar, Inc. for 75 Days and BIO-TECHNE Corp for 63 Days on average.
| FSLR | TECH | |
|---|---|---|
Market Cap | $19.36B | $11.37B |
Volume | 2,069,681 | 3,153,511 |
Sector | Energy | Health |
52-Week High | $318.30 | $72.61 |
52-Week Low | $172.11 | $43.31 |
Typical Hold Time | 75 Days | 63 Days |
Enterprise Value | $17.83B | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
First Solar (FSLR) trades at $178.85, down 0.53% on the day, amid a bearish technical outlook despite strong fundamentals. The stock faces selling pressure with key resistance at $179 and support at $177. Financially, the company delivered robust revenue growth to $5.22 billion in 2025, with a net income margin of 32.47% and a low P/E of 11.11, indicating potential undervaluation. Recent news includes a patent lawsuit filing and high put option volume, reflecting mixed sentiment.
The investment outlook for FSLR is bifurcated: solid profitability and analyst bullishness (59% buy ratings, $267.59 consensus target) contrast with technical weakness and sector headwinds. Upside hinges on earnings beats and legal successes, while risks include interest rate sensitivity and competitive pressures. The stock presents a value opportunity if it can overcome near-term volatility.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About First Solar, Inc.
First Solar designs and manufactures solar photovoltaic panels, modules, and systems for use in utility-scale development projects. The company's solar modules use cadmium telluride to convert sunlight into electricity. This is commonly called thin-film technology. First Solar is the world's largest thin-film solar module manufacturer. It has production lines in Vietnam, Malaysia, the United States, and a new factory under construction in India.
Read more on FSLR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
